MedPath

More Impact AG Secures US Patent for Needle-Free Speedinject Technology

• More Impact AG has been granted a US patent for Speedinject, an innovative needle-free injection technology developed by its subsidiary The Key Unternehmensberatung GmbH.

• The electromagnetically driven system offers a precise, painless, and environmentally friendly alternative for drug administration, particularly targeting diabetes and weight loss treatments.

• With the US pharmaceutical market valued at $634 billion and projected to reach $884 billion in five years, Speedinject is positioned to launch in both EU and US markets by late 2025.

More Impact AG has secured a United States patent for its innovative Speedinject technology, a needle-free injection system developed by its subsidiary The Key Unternehmensberatung GmbH. This patent approval represents a significant milestone in the company's international expansion strategy, particularly targeting the lucrative US pharmaceutical market.
The Frankfurt-based high-tech medical hub announced the patent on May 20, 2025, highlighting Speedinject's potential to transform drug administration for conditions like diabetes and obesity. The technology eliminates traditional needles through an electromagnetically driven system for intramuscular injections, offering patients a more comfortable alternative.

Revolutionary Needle-Free Technology

Speedinject's core innovation lies in its ability to deliver medications without conventional needles. The system provides precise, painless, and hygienic drug administration while significantly reducing medical waste. Unlike traditional prefilled syringes that generate substantial hazardous waste, Speedinject produces minimal waste, limited to a recyclable glass cartridge.
The company is already developing a biodegradable cartridge variant, further enhancing the technology's environmental credentials. This focus on sustainability aligns with growing market demands for eco-friendly medical solutions.

Targeting High-Growth Markets

The technology is particularly well-positioned for the rapidly expanding weight loss medication market. According to industry analyses, weight loss injections are projected to experience a compound annual growth rate (CAGR) exceeding 18% globally between 2023 and 2030.
Speedinject offers significant advantages for patients with needle phobia or those requiring chronic injections. Its patient-friendly design could increase medication adherence while providing a sustainable alternative to conventional injection systems.

Strategic Market Entry

With patents now secured in both the European Union and United States, More Impact AG plans to launch Speedinject by the end of 2025. The US pharmaceutical market, valued at approximately $634 billion in 2024, is expected to grow to $884 billion over the next five years, representing the world's largest pharmaceutical market.
"The granting of the US patent means that Speedinject can now be launched on the market at the end of 2025, not only in the EU, where the relevant patents have already been granted," the company stated in its announcement.

Company Background

More Impact AG (ISIN: DE000A1PG979) operates as a listed high-tech medical hub specializing in developing and supporting innovative medical companies. The firm focuses on securing patents and commercializing product innovations to make cutting-edge medical technologies widely accessible.
The company's business model includes strategic acquisitions and divestitures of companies, divisions, or individual patents. Through Speedinject and other innovations, More Impact aims to contribute to sustainable improvements in global healthcare delivery while capitalizing on emerging market opportunities.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Medtronic's Simplera Sync Sensor for MiniMed 780G System, Expanding CGM Options for Diabetes Management

The FDA has approved Medtronic's Simplera Sync sensor for use with the MiniMed 780G insulin delivery system, expanding continuous glucose monitoring options for diabetes patients in the U.S.
The Simplera Sync is a disposable, all-in-one sensor requiring no fingersticks with SmartGuard or overtape, featuring a simplified two-step insertion process designed to enhance user experience.

Autonomix Medical Secures European Patent for Neuromodulation Technology Targeting Cancer Pain

Autonomix Medical has been granted European Patent No. 3,226,792 for its catheter-based neuromodulation technology, expanding its global intellectual property portfolio to over 80 issued patents.
The patented technology covers methods to sense, ablate, and verify neurological traffic to organs, with initial applications focused on reducing pancreatic cancer pain by targeting the celiac plexus.

FDA Clears ZEISS INTRABEAM 700: Advanced Robotic-Assisted Platform for Intraoperative Radiotherapy

ZEISS INTRABEAM 700 has received FDA 510(k) clearance, offering robotic-assisted precision for intraoperative radiation therapy in neuro-oncology and breast cancer treatment.
The platform features a digital-first architecture with SMART Workflow Efficiency, including sterile single-use applicators, intuitive controls, and Radiance™ treatment planning software for pre-operative simulation.

Enable Injections Secures CE Mark Approval for enFuse Wearable Drug Delivery Platform in Europe

Enable Injections has received European Union Medical Device Regulation CE Mark approval for its enFuse Syringe Transfer System, allowing distribution throughout the EU market.
The enFuse platform enables subcutaneous administration of large-volume biologics and pharmaceuticals, offering an alternative to intravenous delivery with hands-free, hidden needle technology.

ReShape Lifesciences' Diabetes Neuromodulation Device Shows Promise in Preclinical Studies

ReShape Lifesciences presented preclinical data demonstrating their proprietary Diabetes Neuromodulation device can effectively reverse insulin-induced hypoglycemia without cardiac side effects in a swine model of Type 1 diabetes.
The technology utilizes targeted stimulation of the sub-diaphragmatic posterior vagus nerve to rapidly increase blood glucose levels during hypoglycemic episodes, offering a potential alternative to conventional treatments.

SurgiBox Secures US Patents for Portable Sterile Surgery Technology

SurgiBox Inc. has been granted two US patents for its SurgiField™ technology, including an innovative airflow system for clean surgery and a Smart Control Module™ design patent.
The company's portable surgical system combines an inflatable sterile drape with a battery-powered HEPA filtration system, protected by patents across 20 countries.

Miist Therapeutics Secures $7M Seed Funding for Ultra-Rapid Inhaled Drug Delivery Platform

Miist Therapeutics has developed a revolutionary inhaler technology that delivers drugs to the bloodstream 100 times faster than oral medications, with Phase 1 trials showing 92% symptom relief in 2 minutes.
The company's proprietary inhaler creates sterile aqueous drug particles using vibration technology, achieving peak plasma drug levels in under 30 seconds through peripheral lung delivery.

Medtronic Gains FDA Approvals for Percept and Inceptiv Systems

Medtronic's Percept system, a 'pacemaker for the brain,' received FDA approval for managing movement disorders like Parkinson's disease by sending electrical signals to modulate brain rhythms.
The Inceptiv spinal cord stimulator, designed for chronic pain treatment, secured FDA approval with its unique ability to automatically adjust therapy, enhancing pain relief and maintaining stimulation levels.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy